Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials

BACKGROUND: Immune checkpoint inhibitors (ICIs) and genomic biomarker-driven targeted therapies have revolutionized the modern oncologic treatment arsenal. The next step has been to combine targeted agents and ICIs. In doing so, some combination regimens may be more logical than others. PATIENTS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Szeto, C.W., Kurzrock, R., Kato, S., Goloubev, A., Veerapaneni, S., Preble, A., Reddy, S.K., Adashek, J.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850727/
https://www.ncbi.nlm.nih.gov/pubmed/35158206
http://dx.doi.org/10.1016/j.esmoop.2022.100396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850727/
https://www.ncbi.nlm.nih.gov/pubmed/35158206
http://dx.doi.org/10.1016/j.esmoop.2022.100396

Ejemplares similares